Management to hold a conference call at 10:00 a.m. EDT
JERUSALEM--(BUSINESS WIRE)--Jul. 30, 2013--
BioLineRx Ltd. (NASDAQ: BLRX)
(TASE: BLRX),
a biopharmaceutical development company, announced today that it will
release its unaudited financial results for the quarter ended June 30,
2013 on Tuesday, August 6, 2013, before the U.S. markets open.
The Company will host a conference call on Tuesday, August 6 at 10:00
a.m. EDT featuring remarks by Kinneret Savitsky, Ph.D., Chief Executive
Officer of BioLineRx, and Philip Serlin, Chief Financial and Operating
Officer of BioLineRx. The conference call will be available via webcast
and can be accessed through the Investor Relations section of
BioLineRx’s website, www.biolinerx.com,
and www.kcsa.com.
Please allow extra time prior to the call to visit the site and download
any necessary software to listen to the live broadcast. To dial into the
conference call, please dial 1-888-668-9141 from the U.S. or
+972-3-918-0609 internationally.
A replay of the conference call will be available approximately two
hours after completion of the live conference call at www.biolinerx.com
or www.kcsa.com.
A dial-in replay of the call will be available until August 9, 2013;
please dial 1-888-782-4291 from the U.S. or +972-3-9255927
internationally.
About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company.
BioLineRx is dedicated to building a portfolio of products for unmet
medical needs or with advantages over currently available therapies.
BioLineRx’s current portfolio consists of seven clinical stage
candidates: BL-1040, for prevention of pathological cardiac remodeling
following a myocardial infarction, and which has been out-licensed to
Ikaria Inc., is currently undergoing a pivotal CE-Mark registration
trial; BL-5010 for non-surgical removal of skin lesions has completed a
Phase 1/2 study; BL-8040 for treating acute myeloid leukemia (AML) and
other hematological cancers has commenced a Phase 2 study; BL-7040 for
treating inflammatory bowel disease (IBD) has completed a Phase 2a
trial; BL-8020 for hepatitis C (HCV) has commenced a Phase 1/2 study;
BL-1021 for neuropathic pain is in Phase 1 development; and BL-1020 for
schizophrenia. In addition, BioLineRx has five products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases. BioLineRx’s business model is based on acquiring
molecules mainly from biotechnological incubators and academic
institutions. The Company performs feasibility assessment studies and
development through pre-clinical and clinical stages, with partial
funding from the Israeli Government’s Office of the Chief Scientist
(OCS). The final stage includes partnering with medium and large
pharmaceutical companies for advanced clinical development (Phase 3) and
commercialization. For more information on BioLineRx, please visit www.biolinerx.com,
the content of which does not form a part of this press release.
Source: BioLineRx Ltd.
KCSA Strategic Communications
Garth Russell / Todd Fromer
1-212-896-1250
/ 1-212-896-1215
grussell@kcsa.com
/ tfromer@kcsa.com
or
BioLineRx
Ltd.
Tsipi Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il